402 Study: Trial of Assessing the Efficacy and Safety of ITI-007 Adjunctive to Lithium or Valproate in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar Depression)
Brief description of study
We are looking for people who are currently experiencing major depressive episodes associated with bipolar I or bipolar II disorder to take part in our bipolar depression studies. These clinical research studies are designed to help us learn more about an investigational medication for symptoms of bipolar depression.
Detailed description of study
The 402 study is a randomized, double-blind, placebo-controlled research study which is looking at whether an investigational medication, called ITI-007, can improve the symptoms of bipolar depression (bipolar I or bipolar II disorder). It also aims to look at how safe the investigational medication is and whether it impacts the quality of life and well-being of people with bipolar depression, when it is added to existing treatment with a mood stabilizer, specifically lithium or valproate.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Bipolar disorder,Depression,Major depression,Depression,depression
-
Age: Between 18 Years - 75 Years
-
Gender: All
Updated on
20 Nov 2019.
Study ID: 824837